MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of “Moderate Buy” by Analysts

MacroGenics, Inc. (NASDAQ:MGNX) has been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $3.60.

MGNX has been the subject of a number of research reports. Leerink Partners decreased their price target on shares of MacroGenics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. HC Wainwright reiterated a “neutral” rating and set a $2.00 target price on shares of MacroGenics in a report on Monday, November 3rd. Barclays initiated coverage on MacroGenics in a research report on Wednesday, September 17th. They issued an “overweight” rating and a $3.00 target price for the company. Zacks Research upgraded MacroGenics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a research note on Monday.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its holdings in MacroGenics by 55.9% in the third quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 6,161 shares during the period. Quadrature Capital Ltd purchased a new position in shares of MacroGenics during the second quarter valued at approximately $26,000. State of Wyoming bought a new stake in shares of MacroGenics in the 1st quarter worth approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in shares of MacroGenics in the 3rd quarter worth approximately $38,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of MacroGenics in the 2nd quarter worth approximately $28,000. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Stock Down 2.7%

NASDAQ:MGNX opened at $1.42 on Wednesday. The stock has a market cap of $89.83 million, a P/E ratio of -2.49 and a beta of 1.52. The firm’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $1.58. MacroGenics has a twelve month low of $0.99 and a twelve month high of $3.68.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.48) by $0.75. MacroGenics had a negative net margin of 21.99% and a negative return on equity of 40.24%. The business had revenue of $72.84 million during the quarter, compared to analyst estimates of $28.72 million. On average, analysts expect that MacroGenics will post -1.06 EPS for the current fiscal year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.